Amgen, UCB’s Romosozumab Shines in Phase 3

Amgen and UCB Group’s jointly developed osteoporosis candidate romosozumab met the primary endpoint of a statistically significant increase in bone mineral density at 12 months compared with placebo.

Patients treated with romosozumab experienced an increase in BMD at the femoral neck and total hip at 12 months and an increase at the lumbar spine, femoral neck and total hip at six months.

Adverse events were observed in 5.5 percent of patients in the romosozumab arm and 3.7 percent in the placebo.